Can anything shut down the Gold rally?
In a recent transaction, Petersen Floyd F., a director at Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), sold 500 shares of common stock. The shares were sold at a weighted average price of $25.67, amounting to a total sale value of $12,835. This sale was conducted under a pre-established Rule 10b5-1 trading plan. The transaction comes at a time when InvestingPro analysis shows the company trading significantly below its Fair Value, with a strong financial health score of "GREAT" and a market capitalization of $1.2 billion.
In addition to the sale, Petersen acquired 5,122 restricted stock units (RSUs) at no cost. These RSUs are set to vest on June 2, 2026. Furthermore, Petersen was granted stock options for 11,402 shares, also at no cost, with an exercise price of $25.38. These options will vest on June 2, 2026, and expire on June 2, 2035. Notably, while this director transaction occurs, management has been actively buying back shares, according to InvestingPro data.
Following these transactions, Petersen holds 78,031 shares of common stock directly. For deeper insights into insider trading patterns and comprehensive analysis of AMPH’s valuation metrics, check out the detailed Pro Research Report available on InvestingPro.
In other recent news, Amphastar Pharmaceuticals reported its Q1 2025 financial results, revealing a mixed performance. The company missed analyst expectations with an earnings per share (EPS) of $0.51, falling short of the forecasted $0.694, and reported revenue of $170.5 million, which was below the projected $174.35 million. Despite these misses, Amphastar saw a 20% growth in sales of Primatene Mist, indicating strong market demand. The FDA also accepted a Biologics License Application for insulin aspart, marking progress in the company’s pipeline. Meanwhile, JPMorgan downgraded Amphastar’s stock rating from Overweight to Neutral, citing regulatory hurdles and the erosion of its generic drug portfolio. The investment bank also lowered its price target for the company from $45.00 to $30.00. These developments are part of Amphastar’s ongoing efforts to diversify its product offerings and navigate competitive pressures in the pharmaceutical market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.